Austrian Breast & Colorectal Cancer Study Group

Science from the heart of Europe

Maintaining Bone Density in Patients Undergoing Treatment for Breast Cancer: Is There and Adjuvant Benefit?

Gnant M, Dubsky P, Fitzal F, Blaha P, Schoppmann S, Steger G, Marth Ch, Samonigg H, Hüttner K, Fohler H, Rücklinger E, Jakesz, Greil R

Clinical Breast Cancer Supplement

https://www.ncbi.nlm.nih.gov/pubmed/19561003

Endocrine Therapy plus Zoledronic Acid in Premenopausal Breast Cancer

Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch Ch, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Greil R

The New England Journal of Medicine

https://www.ncbi.nlm.nih.gov/pubmed/19213681

Her2/neu – neue Wege, neue Ziele

Mlinertisch B

Wiener Medizinische Wochenschrift

Low p27 expression predicts early relapse and death in postmenopausal hormone receptor-positive breast cancer patients receiving adjuvant tamoxifen therapy

Filipits M, Rudas M, Heinzl H, Jakesz R, Kubista E, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Nader A, Stierer M, Gnant MF, for the Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res 15, 5888-5894, 2009.

Anemia is a significant prognostic factor in local relaspe-free survival of premenopausal primary breast cancer patients receiving adjucant Cyclophosphamide/Methotrexate/5-Fluorouracil chemotherapy

Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifer M, Denison U, Mlinertisch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M

Clinical Cancer Research

https://clincancerres.aacrjournals.org/content/14/7/2082

Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 5-year follow-up of the ABCSG-12 bone-mineral density substudy

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Kainberger F, Kässmann H, Piswanger-Soelkner JC, Seifert M, Ploner F, Menzel Ch, Dubsky P, Fitzal F, Bjelic-Radisic V, Steger G, Greil R, Marth Ch, Kubista E, Samonigg H, Wohlmuth P, Mittlboeck M, Jakesz R

The Lancet Oncology

https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(08)70204-3/fulltext

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)

Mlinertisch B, Tausch Ch, Singer Ch, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel Ch, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R

Breast Cancer Research and Treatment

https://www.ncbi.nlm.nih.gov/pubmed/18158620

Cyclin D1 Expression in Breast Cancer Patients Receivin Adjucant Tamoxifen-Based Therapy

Rudas M, Lehnert M, Huynh A, Jakesz R, Singer Ch, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant M, Filipits M

Clinical Cancer Research

https://www.ncbi.nlm.nih.gov/pubmed/18347178

The potential risk of neoadjuvant chemotherapy in breast cancer patients – results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)

Taucher S, Steger G, Jakesz R, Tausch Ch, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M

Breast Cancer Research and Treatment

https://www.ncbi.nlm.nih.gov/pubmed/18080748

Cyclin D1 expression in breast cancer patients receiving adjuvant tamoxifen-based therapy

Rudas M, Lehnert M, Huynh A, Jakesz R, Singer C, Lax S, Schippinger W, Dietze O, Greil R, Stiglbauer W, Kwasny W, Grill R, Stierer M, Gnant MF, Filipits M, for the Austrian Breast and Colorectal Cancer Study Group.

Clin Cancer Res 14, 1767-1774, 2008.

Zoledronic Acid Prevents Cancer Treatment-Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

Gnant M, Mlineritsch B, Luschin-Ebengreuth G, Grampp S, Kaessmann H, Schmid M, Menzel Ch, Piswanger-Soelkner JC, Galid A, Mittlboeck M, Hausmaninger H, Jakesz R

Journal of Clinical Oncology

https://www.ncbi.nlm.nih.gov/pubmed/17159195

Extended Adjuvant Therapy with Anastrozole Among Postmenopausal Breast Cancer Patients: Results from the Randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a

Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch Ch, Stierer M, Hofbauer F, Renner K, Dadak Ch, Rücklinger E, Samonigg H

Journal of the National Cancer Institute

https://www.ncbi.nlm.nih.gov/pubmed/18073378

Lumpectomy plus tamoxifen or anastrozole with or without whole breast irradiation in women with favorable early breast cancer

Pötter R, Gnant M, Kwasny W, Tausch Ch, Handl-Zeller L, Pakisch B, Taucher S, Hammer J, Luschin-Ebengreuth G, Schmid M, Sedlmayr F, Stierer M, Reiner G, Kapp K, Hofbauer F, Rottenfusser A, Pöstlberger S, Haider K, Draxler W, Jakesz R

International Journal for Radiation Oncology

https://www.ncbi.nlm.nih.gov/pubmed/17363187

A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer

Schippinger W, Samonigg H, Schaberl-Moser R, Greil R, Thödtmann R, Tschmelitsch J, Jagoditsch M, Steger G, Jakesz R, Herbst F, Hofbauer F, Rabl H, Wohlmuth P, Gnant M, Thaler J

British Journal of Cancer

https://www.ncbi.nlm.nih.gov/pubmed/17895886

Pathologic complete response with six compared with three cycles of neoadjuvant epirubicin plus docetaxel and granulocyte colony-stimulating factor in operable breast cancer: results of ABCSG-14

Steger G, Galid A, Gnant M, Mlineritsch B, Lang A, Tausch Ch, Rudas M, Greil R, Wenzel C, Singer Ch, Haid An, Pöstlberger S, Samonigg H, Luschin-Ebengreuth G, Kwasny W, Klug E, Kubista E, Menzel Ch, Jakesz R

Journal of Clinical Oncology

https://www.ncbi.nlm.nih.gov/pubmed/17513805

Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17)

Mlineritsch B, Tausch Ch, Singer Ch, Luschin-Ebengreuth G, Jakesz R, Ploner F, Stierer M, Melbinger E, Menzel Ch, Urbania A, Fridrik M, Steger G, Wohlmuth P, Gnant M, Greil R

Breast Cancer Res Treat DOI 10.1007/s10549-007-9843-x

https://www.ncbi.nlm.nih.gov/pubmed/18158620

The potential risk of neoadjuvant chemotherapy in breast cancer patients—results from a prospective randomized trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-07)

Taucher S, Steger G, Jakesz R, Tausch Ch, Wette V, Schippinger W, Kwasny W, Reiner G, Greil R, Dubsky P, Poestlberger S, Tschmelitsch J, Samonigg H, Gnant M

Breast Cancer Res Treat DOI 10.1007/s10549-007-9844-9

https://www.ncbi.nlm.nih.gov/pubmed/18080748

Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSF

Wenzel C, Bartsch R, Hussian D, Pluschnig U, Altorjai G, Zielinski Ch, Lang A, Haid A, Jakesz R, Gnant M, Steger G

Breast Cancer Res Treat DOI 10.1007/s10549-006-9397-3

https://www.ncbi.nlm.nih.gov/pubmed/17061042

Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis

Jonat W, Gnant M, Boccardo F, Kaufmann M, Rubagotti A, Zuna I, Greenwood M, Jakesz R

The Lancet Oncology

https://www.ncbi.nlm.nih.gov/pubmed/17138220